Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2013

View Archived Issues

Global Blood Therapeutics agent prevents sickling in sickle cell disease

Amgen reports topline results from phase III MENDEL-2 trial

to-BBB begins phase I study of 2B3-201 in healthy volunteers

Aquinox Pharmaceuticals begins phase II trial of AQX-1125 in COPD

Bioheart to begin AdipoCell study for dry macular degeneration

Vical begins phase I/II trial of a therapeutic HSV-2 vaccine

Endo Health Solutions to acquire NuPathe

Lilly joins Combinations Alliance to bring experimental molecules to clinical trials

CHRNA7 and CHRFAM7A gene expression linked to mental disorders

Stelis Biopharma and Pieris collaborate on Anticalin therapeutics in ophthalmology

ChemoCentryx develops CCR4 receptor antagonist for allergic diseases

Pfizer presents new Na(V)1.7 antagonist with promising activity in animal models of pain

Roche patents new Mdm2/p53 inhibitors for cancer

Novel antibodies for autoimmune disorders disclosed by German scientists

Sucampo and Takeda begin phase III program for lubiprostone in pediatric constipation

Takeda Pharmaceutical synthesizes novel PKR1 receptor antagonists

Onconova discontinues phase III study of rigosertib in pancreatic cancer

Researchers at Astex Pharmaceuticals present new FGFR inhibitors for cancer

FDA accepts supplemental BLA for Eylea in diabetic macular edema

Convergence Pharmaceuticals discloses new Na(V)1.7 blockers

GSK and Genmab receive FDA priority review for Arzerra BLA

BioLineRx begins phase I/II trial of BL-7010 in celiac disease

Preclinical and clinical studies evaluate ONO-4059 in B-cell malignancies, CLL

OMS-721 gains orphan status for complement-mediated thrombotic microangiopathies

Bayer HealthCare joins Structural Genomics Consortium for epigenetic research

FDA approves Anoro Ellipta for chronic obstructive pulmonary disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...